Amendment 0002.pdf
PDF 121 KB Posted
- Solicitation number
- HT9402-25-Q-9203
- Issued by
-
Defense Health Agency
About this file
This document is an Amendment (0002) to a Defense Health Agency solicitation for a Pharmacy Uniform Formulary Blanket Purchase Agreement. The amendment specifically adds Vykat XR to the Newly Approved Drug (NAD) List and extends key dates for the solicitation. The RFQ due date and responses to clinical questions have been extended from April 17, 2025, to April 24, 2025. An NDC Price List for Vykat XR has been added to the solicitation, and an updated RFQ document is now part of the procurement package. All other terms and conditions of the original solicitation remain unchanged, and the amendment was issued by Contracting Officer Marsha L. Petersen.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| A0002 RFQ HT9402-25-Q-9203 NAD.pdf | ||
| Price List - Vykat XR - Metabolic Agents - Misc - NA.xlsx | XLSX spreadsheet | |
| Amendment 0001.pdf | ||
| Price List - Otulfi - TIB - IL23.xlsx | XLSX spreadsheet | |
| RFQ HT9402-25-Q-9203 NAD.pdf | ||
| Price List - Raldesy - Antidepressants non-opioid pain - SARI.xlsx | XLSX spreadsheet | |
| Price List - Gomekli - Oncological Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Pyzchiva - TIB - IL23.xlsx | XLSX spreadsheet | |
| Price List - Xromi - Oncological Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Inzirqo - Diuretics - NA.xlsx | XLSX spreadsheet | |
| Price List - Alhemo - Antihemophilic Agents - Non-Factor.xlsx | XLSX spreadsheet | |
| Price List - Ustekinumab-ttwe - TIB - IL23.xlsx | XLSX spreadsheet | |
| Price List - Zunveyl - Alzheimers Agents - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - Romvimza - Oncological Agents - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf |
Show all 16
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
DEFENSE HEALTH AGENCY
7700 ARLINGTON BOULEVARD, SUITE 5101
FALLS CHURCH, VIRGINIA 22042-5101
HT9402-25-Q-9203 0002
April 17, 2025
SUBJECT: Amendment to Solicitation HT9402-25-Q-9203 to add Vykat XR to the Newly Approved Drug (NAD) List, Extend Quote Due Dates, and Extend Responses to Clinical Questions Due Date
1. The purpose of this amendment is to add Vykat XR to the NAD List, extend the quote due date, and extend responses to clinical questions due date.
2. An NDC Price List for Vykat XR has been added to the solicitation.
3. The RFQ due date and responses to clinical questions will be extended as follows:
FROM: April 17, 2025 TO: April 24, 2025
4. An updated RFQ document has been added to the solicitation.
5. All other terms and conditions remain the same.
Marsha L. Petersen Contracting Officer
| 2025-04-17T11:39:28-0500 | |
| PETERSEN.MARSHA.LISA.1021485299 |
File details come from the government source that posted it. Updated .